Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Cancer Research - Tập 70 Số 2 - Trang 440-446 - 2010
Ting‐Chao Chou1
1Author's Affiliation: Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Tóm tắt

Abstract This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics. This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochemistry and biophysics. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations. This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively. Cancer Res; 70(2); 440–6

Từ khóa


Tài liệu tham khảo

Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 68, 621, 10.1124/pr.58.3.10

Goldin, 1957, The employment of combinations of drugs in the chemotherapy of neoplasia: a review, Cancer Res, 17, 635

Greco, 1995, The search for synergy: a critical review from response surface perspective, Pharmacol Rev, 47, 331

Chou, 2007, What is synergy?, Scientist, 21, 15

Chou, 2008, Preclinical versus clinical drug combination studies, Leuk Lymphoma, 49, 2059, 10.1080/10428190802353591

Chou, 1972, Combinatorial analysis of multiple substrate-multiple product enzyme reactions, J Theor Biol, 35, 285, 10.1016/0022-5193(72)90040-9

Chou, 1974, Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition, Mol Pharmacol, 10, 235

Chou, 1976, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands, J Theor Biol, 59, 253, 10.1016/0022-5193(76)90169-7

Chou, 1977, A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems, J Biol Chem, 252, 6438, 10.1016/S0021-9258(17)39978-7

Chou, 1981, Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors, Eur J Biochem, 115, 207, 10.1111/j.1432-1033.1981.tb06218.x

Chou, 1983, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X

Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4

Chou, 1991, The median-effect principle and the combination index for quantitation of synergism and antagonism, Synergism and antagonism in chemotherapy, 61

Chou, 1989, Dose-effect analysis with microcomputers: quantitation of ED50, ID50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics: computer software for the IBM PC series

Chou, 1997, CalcuSyn for Windows: multiple-drug dose-effect analyzer and manual

Chou, 2005, CompuSyn for drug combinations: PC Software and User's Guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values

Michaelis, 1913, Die kinetik der invertinwirkung, Biochem Z, 49, 333

Webb, 1963, Effect of more than one inhibitor, Enzyme and metabolic inhibitors, 66, 10.5962/bhl.title.7320

Chou, 2008, Drug combination against xenograft tumors in nude mice: experimental design, execution, and computerized simulation of synergism and antagonism (an abstract for the mini-symposium), Proc Am Assoc Cancer Res, 49, 997

Chou, 2005, Design, experimentation and computerized automated data analysis of synergistic drug combinations against xenograft tumors by Taxotere and T-900607, Proc Am Assoc Cancer Res, 46, 1167

Mildvan, 1996, Synergy, activity and tolerability of zidovudine and interferon-α in patients with symptomatic HIV-1 infection: AIDS Clinical Trial Group 068, Antivir Ther, 1, 77

Eron, 1995, Treatment with lamivadine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter, N Engl J Med, 333, 1662, 10.1056/NEJM199512213332502

Chou, 1994, Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design, J Natl Cancer Inst, 86, 1517, 10.1093/jnci/86.20.1517

Chou, 2005, Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice, Cancer Chemother Pharmacol, 56, 379, 10.1007/s00280-005-1019-y

Vogt, 1987, Ribavirin antagonizes the effect of azidothymidine on HIV replication, Science, 235, 1376, 10.1126/science.2435003

Chou, 1998, Computerized indexing of drug combinations: prediction of synergism and antagonism of more than two drugs by polygonogram [abstract], FASEB J, 12, 832

Mayer, 2007, Optimizing combination chemotherapy by controlling drug ratios, Mol Interv, 7, 216, 10.1124/mi.7.4.8